Enlivex (ENLV) Q4 2024 earnings summary

Executive summary

• 2024 net loss narrowed to $15.014M from $29.068M in 2023; operating loss fell to $15.888M from $29.395M, while no revenue was generated.

• Cash and cash equivalents were $3.301M and short-term deposits were $20.195M at year-end; management expects current resources to fund development for at least 12 months after filing.

• The audited statements received an unqualified opinion, and internal control over financial reporting was judged effective in all material respects.

Financial highlights

• R&D expense was $10.623M in 2024 vs. $19.012M in 2023; G&A was $4.913M vs. $6.139M.

• Net finance income was $874K in 2024 vs. $327K in 2023; net loss was $15.014M vs. $29.068M.

• Basic and diluted loss per share improved to $0.73 from $1.56; weighted-average shares were 20.514M vs. 18.574M.

• Net cash used in operating activities was $13.008M in 2024 vs. $23.523M in 2023.

Outlook and guidance

• Operations are expected to continue generating losses for at least several years; additional debt, equity financing or partnerships are expected to fund development.

• Current financial resources are expected to support product-candidate development for at least 12 months following the March 31, 2025 filing; longer-term operations depend on additional financial support.

• Long-term profitability depends on financing, development success, commercial or partnership revenue, regulatory approval, market acceptance and competitive conditions.